Management of Recurrent Esophageal Squamous Cell Carcinoma (ESCC) Post-Definitive Chemoradiotherapy (dCRT)

1. Initial Workup After Suspected Recurrence

• Upper GI endoscopy + biopsy - confirm histologic recurrence vs. radiation fibrosis/necrosis; obtain tissue for PD-L1 (CPS), HER2, MMR/MSI, and molecular profiling
• CT chest/abdomen/pelvis (contrast) - assess locoregional extent and distant metastases
• PET-CT - most sensitive for detecting oligometastatic vs. widely metastatic disease; guides candidacy for salvage local therapy
• Endoscopic ultrasound (EUS) - restage depth of invasion and lymphadenopathy for surgical planning
• Bronchoscopy - if airway invasion or tracheoesophageal fistula is suspected (especially mid-thoracic tumors post-radiation)
• Blood markers - CEA, cell-free tumor DNA for monitoring

2. Salvage Esophagectomy

• Residual/recurrent disease confined to the esophagus ± adjacent lymph nodes (resectable staging on restaging PET/CT + EUS)
• No prior radiotherapy field overlap preventing R0 resection
• Adequate cardiopulmonary reserve (PFTs, LVEF)
• Performance status ECOG 0-1
• Must be performed at a high-volume esophageal surgery center

• R0 resection achieved in ~79-85% of cases
• 5-year survival post-salvage esophagectomy: approximately 25-40% in selected series (better than non-surgical salvage)
• Re-recurrence rate remains high: 70-74%, often locoregional (21-50%) or distant (29-37%)
• Morbidity is significantly higher than primary esophagectomy due to radiation-induced tissue damage, fibrosis, and impaired healing

• Minimally invasive esophagectomy (MIE) preferred where feasible - reduces pulmonary complications in irradiated fields
• Conduit: gastric pull-up is standard; colonic/jejunal interposition if stomach is in radiation field
• Anastomotic leak rates higher post-dCRT; cervical anastomosis preferred
• Perioperative nutrition optimization mandatory (often requires pre-op feeding tube)

3. Salvage Lymphadenectomy (for Cervical LN Recurrence)

• For isolated cervical lymph node recurrence without esophageal lumen involvement, salvage lymphadenectomy generally yields better outcomes than RT or CRT alone
• Cancers 2024 (Mitamura et al.): cervical LN-only recurrence has the best prognosis with surgical resection
• Combined adjuvant therapy (CRT post-lymphadenectomy) does not consistently improve OS vs. surgery alone in retrospective data, but is often given given high re-recurrence rates

4. Re-irradiation / Salvage CRT

• Local/locoregional recurrence outside prior high-dose radiation field
• Unresectable locoregional recurrence

• Cumulative dose to spinal cord and other OARs is the limiting factor
• IMRT/VMAT preferred for dose conformality and OAR sparing
• A 2023 retrospective series (Xiang et al.) showed IMRT/VMAT re-irradiation achieves local control in selected patients
• Proton beam therapy (PBT) is increasingly used for re-irradiation - superior dose distribution reduces toxicity in previously irradiated tissue; available at specialized centers
• Concurrent chemotherapy (cisplatin-based or paclitaxel-based) can be added if patient is fit, but toxicity (esophagitis, fistula risk) is substantially higher in the re-irradiation setting

5. Endoscopic Salvage Therapies

• Endoscopic Submucosal Dissection (ESD) - for T1a/T1b residual/recurrent lesions with no nodal spread; highly selected
• Photodynamic Therapy (PDT) - porfimer sodium + laser activation; used for local failure after dCRT; [Gastrointest Endosc 2016 (Hatogai et al.)] demonstrated feasibility in selected patients
• Endoscopic mucosal resection (EMR) - for flat superficial lesions
• Limitation: post-radiation fibrosis makes en bloc resection technically difficult and increases perforation risk

6. Systemic Therapy - Advanced/Metastatic Recurrence

First-Line (if not received previously or if CTRT was not combined with systemic immunotherapy)

• CheckMate-648 (nivolumab + chemo): improved OS vs. chemo alone in ESCC with PD-L1 tumor proportion score ≥1%; nivolumab + ipilimumab dual immunotherapy also showed benefit vs. chemo alone
• KEYNOTE-590 (pembrolizumab + 5-FU/cisplatin): improved OS in ESCC with CPS ≥10
• ORIENT-15 (sintilimab), RATIONALE-306 (tislelizumab): confirmed ICI + chemo benefit in ESCC

Second-Line Systemic Therapy

• Nivolumab (CheckMate-017/CheckMate-032): approved 2nd-line for ESCC after platinum-based therapy
• Pembrolizumab (KEYNOTE-181): superior OS vs. chemo in ESCC with CPS ≥10
• Tislelizumab (RATIONALE-302): non-inferior/superior to chemo in 2nd-line ESCC
• Camrelizumab (ESCORT trial): 2nd-line ESCC benefit, particularly in Asian populations

• Paclitaxel ± ramucirumab
• Docetaxel monotherapy
• Irinotecan ± 5-FU (FOLFIRI)
• Apatinib (anti-VEGFR2) - has shown benefit in 3rd-line ESCC (primarily Asian data)

Novel/Emerging Targets (2025-2026)

• Anti-TIGIT agents (e.g., tiragolumab): under investigation in combination with atezolizumab for ESCC
• Antibody-drug conjugates (ADCs): investigational in ESCC
• CLDN18.2 positivity (uncommon in ESCC vs. adenocarcinoma) - zolbetuximab approved for gastroesophageal adenocarcinoma but not standard for ESCC

7. Palliative and Supportive Measures

Dysphagia Management

• Self-expanding metal stents (SEMS): technical success ~95%, clinical dysphagia relief in ~80%; median survival after stenting 78-83 days
  • Covered SEMS preferred for malignant stricture and fistula sealing (>90% fistula closure)
  • Caution post-radiation: stent placement in previously irradiated field carries increased risk of fistula, aortic erosion, hemorrhage; requires MDT discussion and explicit patient counseling
  • ESGE: stent placement during concurrent RT is contraindicated
• Palliative brachytherapy - for dysphagia relief; single-dose or fractionated; good local control in 3-4 months
• Laser/argon plasma coagulation (APC) - for tumor debulking and dysphagia palliation
• Dilation - temporary; risk of perforation in post-RT stenosis

Nutritional Support

• Nasogastric/nasoenteric feeding or percutaneous endoscopic gastrostomy (PEG) for nutritional optimization
• Formal dietitian involvement; high-calorie, high-protein supplementation
• Address cancer cachexia proactively

Pain Management

• WHO analgesic ladder; opioids for tumor-related pain
• Interventional: celiac plexus block for refractory pain

Psychological Support

• Recurrent cancer carries high distress burden; palliative care team involvement from point of recurrence diagnosis is recommended

8. MDT Framework - Decision Algorithm

Recurrence confirmed post-dCRT
           ↓
PET-CT restaging + EUS + endoscopy
           ↓
    ┌──────────────────────────────┐
    │ Locoregional only?           │
    └──────────────────────────────┘
          ↓ YES                    ↓ NO (distant mets)
   ┌──────────────┐         Systemic therapy
   │ Resectable?  │         (ICI ± chemo)
   └──────────────┘
     ↓ YES     ↓ NO
Salvage    Re-irradiation /
esophagec-  salvage CRT /
tomy (high  endoscopic Rx
volume      (if superficial)
center)
           ↓
   Fit for systemic?
   Add ICI + chemo
   if not previously given

9. Summary of Key Evidence (Recent Literature)

Key Clinical Pearls

1. Always rebiopsy at recurrence - confirm ESCC histology and obtain fresh biomarkers (PD-L1, MSI, HER2)
2. Salvage esophagectomy should only be offered at high-volume centers with dedicated esophageal teams
3. Esophageal stenting in post-RT patients carries elevated fistula/hemorrhage risk - requires explicit MDT decision and patient counseling
4. ICI + chemo is now the standard of care for advanced/metastatic recurrence in PD-L1+ ESCC (CPS ≥1)
5. Proton beam therapy is an emerging option for re-irradiation to reduce toxicity in previously irradiated fields
6. Palliative care integration from the time of recurrence detection is recommended regardless of treatment intent

ESR in Multiple Myeloma

The Cutoff: >100 mm/hr (Westergren method)

Why ESR Is So Elevated in Myeloma

Important Context

ESR Is NOT in the Formal Diagnostic Criteria

1. Clonal bone marrow plasma cells ≥10% or biopsy-proven plasmacytoma
2. Plus one or more CRAB criteria (hyperCalcemia, Renal insufficiency, Anemia, Bone lesions) or SLiM criteria (≥60% plasma cells, serum FLC ratio ≥100, >1 MRI focal lesion)
3. M protein on SPEP/SFLC assay, Bence Jones protein on urine SPEP

Practical Takeaway

• ESR >100 mm/hr = red flag, always investigate for myeloma (and other serious diseases)
• Confirmatory tests: SPEP, serum free light chains (FLC), urine SPEP (Bence Jones protein), bone marrow biopsy
• A normal ESR does not exclude myeloma, particularly in light-chain or non-secretory subtypes